Skip to main content
Log in

Further considerations on adverse reactions to radiopharmaceuticals

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Hesse B, Vinberg N, Berthelsen AK, Ballinger JR. Adverse events in nuclear medicine – cause for concern? Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-012-2071-6

  2. Santos-Oliveira R, Machado M. Pitfalls with radiopharmaceuticals. Am J Med Sci. 2011;342:50–3.

    Article  PubMed  Google Scholar 

  3. Silberstein EB, Ryan J. Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. J Nucl Med. 1996;37:185–92.

    PubMed  CAS  Google Scholar 

  4. Hesslewood SR, Keeling DH. Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med. 1997;24:1179–82.

    PubMed  CAS  Google Scholar 

  5. Silberstein EB. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. J Nucl Med. 1998;39:2190–2.

    PubMed  CAS  Google Scholar 

  6. Kusakabe K, Okamura T, Kasagi K, Komatani A, Sato Y, Matsuda H, et al. The 27th report on survey of the adverse reaction to radiopharmaceuticals (the 30th survey in 2004). Kaku Igaku. 2006;43:23–35.

    PubMed  Google Scholar 

  7. Kusakabe K, Arano Y, Okamura T, Kasagi K, Komatani A, Matsuda H, et al. The 28th report on survey of the adverse reaction to radiopharmaceuticals (the 31st survey in 2005). Kaku Igaku. 2007;44:29–42.

    PubMed  Google Scholar 

  8. Kusakabe K, Arano Y, Okamura T, Kasagi K, Komatani A, Matsuda H, et al. The 29th report on survey of the adverse reaction to radiopharmaceuticals (the 32nd survey in 2006). Kaku Igaku. 2008;45:19–35.

    PubMed  CAS  Google Scholar 

  9. Matsuda H, Arano Y, Okazawa H, Okamura T, Mizumura S, Yokoyama K, et al. The 30th report on survey of the adverse reaction to radiopharmaceuticals (the 33rd survey in 2007). Kaku Igaku. 2009;46:29–41.

    PubMed  Google Scholar 

  10. EANM Radiopharmacy Committee. http://www.eanm.org/committees/radiopharmacy/edu.php?navId=226

  11. Hesslewood SR. European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 2000. Eur J Nucl Med Mol Imaging. 2002;29:BP13–19

    Article  PubMed  CAS  Google Scholar 

  12. Nota Informativa Importante su Scintimun (besilesomab) (10/11/2011) http://www.agenziafarmaco.gov.it/it/content/nota-informativa-importante-su-scintimun-besilesomab-10112011

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Massimo Salvatori.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salvatori, M., Treglia, G. & Mores, N. Further considerations on adverse reactions to radiopharmaceuticals. Eur J Nucl Med Mol Imaging 39, 1360–1362 (2012). https://doi.org/10.1007/s00259-012-2120-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-012-2120-1

Keywords

Navigation